Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A Houston 503A mail-order compounder focused on weight loss, peptides/longevity, and hormones — with an accreditation gap worth knowing.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
ReviveRx is a consumer-facing 503A mail-order compounding pharmacy popular in the peptide/longevity crowd. It’s patient-specific 503A (state-regulated), not a 503B outsourcing facility.
ReviveRx (reviverx.com; Houston, TX) describes itself as a licensed 503A mail-order compounding pharmacy, founded 2016 and compounding since 2018 [1]. It is not on the FDA 503B list [3]. On accreditation, ReviveRx does not appear in ACHC’s PCAB directory and makes no PCAB claim we could find [2] — so, unlike Empower or Hallandale, its compounding isn’t PCAB-accredited as far as the accreditor’s own registry shows. The site references a “successful FDA inspection,” which we could not independently verify. Note the correct domain is reviverx.com (revive-rx.com is an unrelated site).
On-audience: weight loss, a peptide & longevity line, men’s and women’s hormone therapy, sexual wellness, thyroid, and fertility [1]. The company says it ships to 45 states plus Puerto Rico [1].
As a 503A pharmacy, oversight sits primarily with the Texas board of pharmacy, not FDA CGMP inspection. We found no FDA warning letter for ReviveRx in public sources, and it is not on the FDA 503B list [3]. Absence from federal databases is not an exhaustive clean record for a 503A.
A legitimate, on-audience 503A with clear peptide/GLP-1/HRT offerings and real consumer following. The honest caveat is the accreditation gap: no PCAB found in ACHC’s registry and only a self-stated (unverified) FDA inspection — so it sits a notch below the PCAB-verified operators here on independent quality signals.